Aleksandar Radujkovic
- Hematology top 2%
- Hematopoietic Stem Cell Transplantation 25
- Acute Myeloid Leukemia Research 18
- Chronic Myeloid Leukemia Treatments 8
- Transplantation top 5%
- Renal Transplantation Outcomes and Treatments 3
-
- Lymphoma Diagnosis and Treatment 5
- Vitamin D Research Studies 3
- Infectious Diseases top 10%
- COVID-19 Clinical Research Studies 3
- Nutrition and Dietetics top 5%
-
- Chronic Lymphocytic Leukemia Research 3
- Co-authors
- Thomas LuftPeter DregerUta MerleTheresa HippchenShilpa Tiwari‐HecklerAxel BennerOlaf PenackAnthony D. Ho
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Aleksandar Radujkovic
52 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 100
- Hematology 471
- Transplantation 68
- Pathology and Forensic Medicine 268
- Infectious Diseases 239
- Nutrition and Dietetics 193
Countries citing papers authored by Aleksandar Radujkovic
This map shows the geographic impact of Aleksandar Radujkovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleksandar Radujkovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleksandar Radujkovic more than expected).
Fields of papers citing papers by Aleksandar Radujkovic
This network shows the impact of papers produced by Aleksandar Radujkovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleksandar Radujkovic. The network helps show where Aleksandar Radujkovic may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Aleksandar Radujkovic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 15 | |
| 2 | 2023 | 1 | |
| 3 | 2022 | 2 | |
| 4 | 2021 | 14 | |
| 5 | 2021 | 6 | |
| 6 | 2021 | 46 | |
| 7 | 2021 | 49 | |
| 8 | 2020 | 7 | |
| 9 | 2020 | 32 | |
| 10 | 2020 | 6 | |
| 11 | 2019 | 13 | |
| 12 | 2019 | 89 | |
| 13 | 2017 | 62 | |
| 14 | 2016 | 4 | |
| 15 | 2016 | 22 | |
| 16 | 2014 | 2 | |
| 17 | 2011 | 4 | |
| 18 | 2009 | 16 | |
| 19 | Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. | 2006 | 15 |
| 20 | 2005 | 78 |
About Aleksandar Radujkovic
Aleksandar Radujkovic is a scholar working on Hematology, Transplantation, Genetics, Biological Psychiatry and Pathology and Forensic Medicine, having authored 53 papers that have together received 1.3k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (25 papers), Acute Myeloid Leukemia Research (18 papers), Chronic Myeloid Leukemia Treatments (8 papers), Lymphoma Diagnosis and Treatment (5 papers), Renal Transplantation Outcomes and Treatments (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Vitamin D Research Studies (3 papers) and COVID-19 Clinical Research Studies (3 papers). The work is most often cited by research in Hematology (471 citations), Transplantation (68 citations), Pathology and Forensic Medicine (268 citations), Infectious Diseases (239 citations) and Nutrition and Dietetics (193 citations). Aleksandar Radujkovic has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Thomas Luft, Peter Dreger, Uta Merle, Theresa Hippchen, Shilpa Tiwari‐Heckler, Axel Benner, Olaf Penack, Anthony D. Ho, Carsten Müller‐Tidow and Natália Becker. Their work appears in journals such as Blood, Haematologica, Bone Marrow Transplantation, Journal of Clinical Oncology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.